Vamorolone Safely Improves Muscle Function in DMD Boys, Trial Finds

Vamorolone Safely Improves Muscle Function in DMD Boys, Trial Finds

295640

Vamorolone Safely Improves Muscle Function in DMD Boys, Trial Finds

Top-line data from the VISION-DMD Phase 2b clinical trial evaluating vamorolone in boys with Duchenne muscular dystrophy (DMD), showed efficacy across primary and secondary study goals. The investigational therapy was also well-tolerated with a favorable safety profile. Santhera Pharmaceuticals, which is developing the treatment in partnership with ReveraGen BioPharma, plans to apply to the U.S. Food and Drug Administration (FDA) early in 2022, requesting a priority review of vamorolone to treat DMD.  “We are thrilled about the…

You must be logged in to read/download the full post.